ClinicalTrials.gg

Program

quizartinib

Also written as “Quizartinib”, “AC220” and “Quizartinib High Dose”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by 2 companies.

Furthest: phase 3, since Jan 15, 201422 company-led studies, 5 open or runningNext primary completion: May 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo214 open or runningphase 3since Jan 15, 2014Apr 17, 2007May 1, 2027phase 2 · NCT03793478
Kura Oncology11 open or runningphase 1since Feb 9, 2023Feb 9, 2023Apr 2030phase 1 · NCT05735184

Also a collaborator on its studies: quotient-sciences and ambit-biosciences-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 17, 2007.

  1. Jan 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT02668653 · 539 enrolled · United States, Argentina, Australia and more
  2. Feb 2, 2016Phase 1 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT02675478 · 17 enrolled · Japan
  3. Jul 13, 2016Phase 1 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT02834390 · 7 enrolled · Japan
  4. Dec 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT02984995 · 37 enrolled · Japan
  5. May 17, 2018Phase 1 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT03552029 · 10 enrolled · United States
  6. Oct 18, 2018Phase 1 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT03723681 · 7 enrolled · China
  7. Jan 2, 2019Phase 2 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT03793478 · 65 enrolled · United States, Belgium, Canada and more
  8. Jul 2, 20202 phase 1 studiesDaiichi Sankyo · NCT04459598, NCT04473664
  9. Jul 2, 2020Early phase 1 study in Healthy SubjectsDaiichi Sankyo · NCT04459585 · 20 enrolled · United States
  10. Mar 5, 2021Phase 1 study in Healthy SubjectsDaiichi Sankyo · NCT04796831 · 8 enrolled · United Kingdom
  11. Feb 9, 2023Kura Oncology's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT05735184 · 420 planned · United States
  12. Aug 14, 2024Phase 3 study in LeukemiaDaiichi Sankyo · NCT06578247 · 700 enrolled · United States, Australia, Austria and more
  13. Dec 13, 20243 phase 1 studiesDaiichi Sankyo · NCT06772246, NCT06740825, NCT06740799
  14. Feb 7, 2025Phase 2 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT06824168 · 130 planned · United States, Australia, Brazil and more

Ahead

  1. May 1, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT03793478
  2. Jun 6, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteDaiichi Sankyo · NCT06824168
  3. Apr 2030Primary completion: phase 1 study in Leukemia, Myeloid, AcuteKura Oncology · NCT05735184
  4. Jun 26, 2030Primary completion: phase 3 study in LeukemiaDaiichi Sankyo · NCT06578247

TargetBeta

“Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06824168Leukemia, Myeloid, Acute · United States, Australia, Brazil and more2RecruitingDaiichi SankyoJun 6, 2028130
NCT06772246Healthy Subjects · United States1CompletedDaiichi SankyoJun 12, 202570
NCT06740825Healthy Subjects · United States1CompletedDaiichi SankyoDec 9, 202432
NCT06740799Hepatic Impairment · United States1RecruitingDaiichi SankyoOct 31, 202612
NCT06578247Leukemia · United States, Australia, Austria and more3Active, not recruitingDaiichi SankyoJun 26, 2030700
NCT05735184Leukemia, Myeloid, Acute · United States1RecruitingKura OncologyApr 2030420
NCT04796831Healthy Subjects · United Kingdom1CompletedDaiichi SankyoJun 11, 20218
NCT04473664Hepatic Impairment · United States1CompletedDaiichi SankyoJul 22, 202112
NCT04459598Healthy Subjects · United States1CompletedDaiichi SankyoOct 14, 202032
NCT04459585Healthy Subjects · United StatesEarly 1CompletedDaiichi SankyoOct 20, 202020
NCT03793478Leukemia, Myeloid, Acute · United States, Belgium, Canada and more2Active, not recruitingDaiichi SankyoMay 1, 202765
NCT03723681Leukemia, Myeloid, Acute · China1CompletedDaiichi SankyoMar 3, 20227
NCT03552029Leukemia, Myeloid, Acute · United States1TerminatedDaiichi SankyoApr 1, 202110
NCT02984995Leukemia, Myeloid, Acute · Japan2CompletedDaiichi SankyoMar 28, 201837
NCT02834390Leukemia, Myeloid, Acute · Japan1CompletedDaiichi SankyoOct 19, 20177
NCT02675478Leukemia, Myeloid, Acute · Japan1CompletedDaiichi SankyoNov 13, 201817
NCT02668653Leukemia, Myeloid, Acute · United States, Argentina, Australia and more3CompletedDaiichi SankyoAug 13, 2021539
NCT02039726Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedDaiichi SankyoFeb 22, 2018367
NCT01565668Leukemia, Myeloid, Acute · United States, France, Italy and more2CompletedDaiichi SankyoMar 201576
NCT01468467Leukemia, Myeloid, Acute · United States1CompletedDaiichi SankyoMar 201513
NCT01390337Leukemia, Myeloid, Acute · United States1CompletedDaiichi SankyoFeb 201519
NCT00462761Leukemia, Myeloid, Acute · United States, Georgia1CompletedDaiichi SankyoMar 200976

How it is read

Names in the registry

  • “Quizartinib”, 15 entries
  • “AC220”, 5 entries
  • “Quizartinib High Dose”, 1 entry
  • “Quizartinib Low Dose”, 1 entry
  • “Quizartinib dihydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.